Park Ha Biological Technology sold 1,080,000 Class A ordinary shares at $2.75 each and raised approximately US $2,970,000, while issuing warrants for 1,845,452 shares. The proceeds are earmarked for Working Capital and corporate purposes, and the warrants are immediately exercisable at US $1.1 with a five-year term.
Key Highlights
- The warrants are exercisable immediately and expire five years after issuance.
- The securities were sold offshore to non-U.S. Persons under Regulation S and remain subject to transfer restrictions.
- Raised approximately US $2,970,000 through a private placement.
- Sold 1,080,000 Class A ordinary shares at $2.75 per share.
Park Ha Biological Technology Co. Ltd. (NASDAQ: BYAH) raised approximately US $2,970,000 through a private Placement that sold 1,080,000 Class A ordinary shares at $2.75 per share. The transaction also provides participating non-U.S. Investors with warrants covering 1,845,452 Class A ordinary shares.
Five-Year Warrants Accompany PIPE
The warrants can be exercised immediately after issuance and carry a five-year term. The Class A ordinary shares have a Par Value of US $0.008 per share. During the relevant distribution compliance period, transfers to U.S. persons are restricted unless registration or an available exemption applies. The Warrant terms include customary anti-dilution provisions for share dividends, splits and similar transactions. The securities purchase agreement and warrant documents also contain customary representations, warranties, covenants, agreements and indemnification obligations.
FAQs
Q: How much did Park Ha Biological Technology raise in its PIPE?
A: Park Ha Biological Technology raised approximately US $2,970,000 in gross proceeds. The private placement involved 1,080,000 Class A ordinary shares priced at $2.75 each.
Q: What warrants did Park Ha Biological Technology issue?
A: Participating investors received warrants covering 1,845,452 Class A ordinary shares. The warrants are immediately exercisable at US $1.1 per Warrant Share and have a five-year term.
Q: How will Park Ha Biological Technology use the PIPE proceeds?
A: It states only that the private placement raised approximately US $2,970,000 through the sale of 1,080,000 Class A ordinary shares.
Download Free Report – Explore 3 Stock Ideas & Industry Insights
Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.
All investments involve risk—consider independent advice before making any investment decisions.
View 3 Research Reports
Disclaimer:
Kalkine Equities LLC, with Delaware File Number 4697384, Foreign Qualification Registration in California File Number 202109211078, and Texas File Number 805521396, is authorized to provide general advice only. The information on https://kalkine.com/ does not take into account any of your investment objectives, financial situation or needs. You should consider the appropriateness of advice taking into account your own objectives, financial situation and needs and seek independent financial advice before making any financial decisions. The link to our Terms and Conditions and Privacy Policy has been provided for your reference. On the date of publishing the reports (mentioned on the website), employees and/or associates of Kalkine do not hold positions in any of the stocks covered on the website. These stocks can change any time and readers of the reports should not consider these stocks as advice or recommendations later.